Hacı Murat GÜNEŞ, Tayyar GÖKDENİZ, İbrahim Oğuz KARACA, Gültekin GÜNHAN DEMİR, Filiz Kızılırmak, Ekrem GÜLER, Gamze BABÜR GÜLER, Mehmet Onur OMAYGENÇ, Umeyir SAVUR, Ersin İBİŞOĞLU, Bilal BOZTOSUN

Uzun Segment Koroner Lezyonlarda Biyoeriyebilen Stentlerin Güvenlik ve Etkinlik Sonlanımları

Giriş: Uzun segment lezyonlarda biyoeriyebilen stentlerin (BRS) kullanımı ile ilgili sınırlı bilgimiz olduğundan hem BRS-BRS hem de İlaç salınımlı metal stent (DES)-BRS overlap uygulanan hastaların klinik sonuçlarını değerlendirmeyi planladık. Hastalar ve Yöntem: Tek merkezli, kesitsel planlanan; Ocak 2013-Haziran 2016 tarihleri arasında uzun segment lezyonlara (> 28 mm) BRS yerleştirilmesi planlanan 97 hasta ve 100 lezyon çalışmaya alındı. Otuz hasta ve 30 lezyonda BRS-BRS overlap uygulanırken , 67 hasta 70 lezyona DES-BRS overlap uygulandı. Akut işlem başarısı ve MACE (ölüm, stent trombozu, hedef damara yeniden girişim) değerlendirildi. Bulgular: Akut işlem başarısı %97.1 idi. Tüm hasta grubunda toplam MACE 6 (%6.2) hastada gelişirken, DES-BRS grubunda 4 (%5.9), BRS-BRS grubunda 2 (%6.6) hastada MACE gerçekleşti. Sonuç: Uzun segment lezyonlarda BRS kullanımı seçenek olarak değerlendirilebilinir. BRS-BRS veya BRS-DES overlap yapacak şekilde yerleştiriken kısa segment overlap olacak şekilde gerçekleştirilmelidir.

Anahtar Kelimeler:

Biyoeriyebilen stentler, overlap, hibrit tekniği

Safety and Efficacy Outcomes of Bioresorbable Scaffolds in Long Segment Coronary Lesions

Introduction: There is limited knowledge about the use of bioresorbable scaffolds (BRSs) in long segment coronary artery lesions. We aimed to evaluate the clinical outcomes of BRS-BRS and drug eluting stents (DESs)-BRS overlapping applications. Patients and Methods: Cross-sectional, single-center study between 2013 and 2016 enrolled 97 patients and 100 lesions scheduled for BRS placement in long segment lesions (> 28 mm). BRS-BRS overlap was performed in 30 patients and 30 lesions, DES-BRS overlap was performed in 67 patients and 70 lesions. Acute procedural success and major adverse cardiac events (MACE) (death, stent thrombosis, and target lesion reintervention) were assessed. Results: Acute procedural success was 97.1% in the overall group. MACE was observed in 6 patients (6.2%) in the entire group, 4 (5.9%) in the DES-BRS group, and 2 (6.6%) in the BRS-BRS group. Conclusion: BRS use might be a safe and effective option for the treatment of long segment lesions. Both BRS-BRS overlap and BRS-DES overlap may be performed with short overlap segment.

Keywords:

Bioresorbable scaffolds, overlapping, hybrid strategy,

PDF

___

1. Ormiston JA, Serruys PWS. Bioabsorbable coronary stents. Circ Cardiovasc Interv 2009;2:255-60.
2. Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable caffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J 2012;33:16-25.
3. Onuma Y, Dudek D, Thuesen L, Webster M, Nieman K, Garcia-Garcia HM, et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv 2013;6:999-1009.
4. Räber L, Jüni P, Löffel L, Wandel S, Cook S, Wenaweser P, et al. Impact of stent overlap on angiographic and long-term clinical outcome in patients undergoing drug-eluting stent implantation. J Am Coll Cardiol 2010;55:1178-88.
5. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005;112:270-8.
6. Kitabata H, Loh JP, Pendyala LK, Badr S, Dvir D, Barbash IM, et al. Safety and efficacy outcomes of overlapping second-generation everolimus-eluting stents versus first-generation drug-eluting stents. Am J Cardiol 2013;112:1093-8.
7. Biscaglia S, Ugo F, Ielasi A, Secco GG, Durante A, D’Ascenzo F, et al. Bioresorbable scaffold vs. second generation drug eluting stent in long coronary lesions requiring overlap: a propensity-matched comparison (the UNDERDOGS study). Int J Cardiol 2016;208:40-5.
8. Ho HH, Jafary FH, Loh KK, Tan JK, Ooi YW, Ong PJ. Deliverability of integrity coronary stents in severely tortuous coronary arteries: a preliminary experience. J Invasive Cardiol 2012;24:650-4.
9. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Chuang YC, et al. Patterns of intravascular ultrasound and coronary angiography in 1155 lesions. Circulation 1995;91:1959-65.
10. Wiebe J, Liebetrau C, Dörr O, Most A, Weipert K, Rixe J, et al. Feasibility of everolimus- eluting bioresorbable vasculars caffolds in patients with chronic total occlusion. Int J Cardiol 2015;179:90-4.
11. Džavík V, Colombo A. The absorb bioresorbable vascular scaffold in coronary bifurcations: insights from bench testing. JACC Cardiovasc Interv 2014;7:81-8.
12. Gori T, Schulz E, Hink U, Wenzel P, Post F, Jabs A, et al. Early outcome after implantation of absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. Euro Intervention 2014;9:1036-41.
13. Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-Ehrenreich KL, Giddings VL, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 2011;123:1400-9.
14. Murasato Y, Hikichi Y, Nakamura S, Kajiya F, Iwasaki K, Kinoshita Y, et al. Recent perspective on coronary bifurcation intervention: statement of the “Bifurcation Club in KOKURA”. J Interv Cardiol 2010;23:295-304.
15. Rikhtegar F, Wyss C, Stok KS, Poulikakos D, Müller R, Kurtcuoglu V, et al. Hemodynamics incoronary arteries with overlapping stents. Journal of Biomechanics 2014;47:505-11.
16. Farooq V, Serruys PW, Heo JHW, et al. Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice. JACC Cardiovasc Interv 2013;6:523-2.
17. Farooq V, Onuma Y, Radu M, Okamura T, Gomez-Lara J, Brugaletta S, et al. Optical coherence tomography (OCT) of overlapping bioresorbable scaffolds: from bench work to clinical application. Euro Intervention 2011;7:386-99.
18. Gil RJ, Bil J, Pawłowski T, Yuldashev N, Kołakowski L, Jańczak J, et al. The use of bioresorbable vascular scaffold Absorb BVS® in patients with stable coronary artery disease: one-year results with special focus on the hybrid bioresorbable vascular scaffolds and drug eluting stents treatment. Kardiol Pol 2016;74:627-33.
19. Yew KL. Overlapping technique for hybrid percutaneous coronary intervention strategy utilising drug eluting stent and ABSORB bioresorbable vascular scaffold. Int J Cardiol 2015;178:e8-e10.
20. Serruys PW, Chevalier B, Sotomi Y, Cequier A, Carrié D, Piek JJ, et al. Comparison of an everolimus-eluting bioresorbable scaf oldwith an everolimus-eluting metallic stent for the treatmentof coronary artery stenosis (ABSORB II): a 3 year, randomised,controlled, single-blind, multicentre clinical trial. Lancet 2016;388:2479-91.
21. Polimeni A, Anadol R, Münzel T, Indolfi C, De Rosa S, Gori T. Long-term outcome of bioresorbable vascular scaffolds for the treatment of coronary artery disease: a meta-analysis of RCTs. BMC Cardiovasc Disord 2017;17:147.

ISSN: 2149-2972
Yayın Aralığı: Yılda 3 Sayı
Başlangıç: 1990
Yayıncı: Sağlık Bilimleri Üniversitesi, Kartal Koşuyolu Yüksek İhtisas Eğitim ve Araştırma Hastanesi